ReviewJournal of leukocyte biology2022
Animal models for studies of HIV-1 brain reservoirs.
Review in Journal of leukocyte biology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 26 citations in OpenAlex.
- Vascularized human brain organoids as a model of the brain-peripheral axis in HIV-1 neuropathogenesis.Scientific reports · 2026Article
- Prolonged QT Interval in HIV-1 Infected Humanized Mice Treated Chronically with Dolutegravir/Tenofovir Disoproxil Fumarate/Emtricitabine.International journal of molecular sciences · 2026Article
- Osteopontin knockdown reverses HIV-induced cognitive deficits and influences motivation-related behavior.Brain, behavior, and immunity · 2026Article
- Imaging the neurohiv brain in animal models: past, present, and future-toward longitudinal, whole-brain aging phenotypes.Frontiers in aging neuroscience · 2026Review
- Isolated Bilateral Cerebellar Dysfunction as the Initial Manifestation of HIV Infection: A Diagnostic Challenge, Case Report, and Literature Review.Cerebellum (London, England) · 2025Review
- Recent advances in nanotherapeutics for HIV-associated neurocognitive disorders and substance use disorders.Nanomedicine (London, England) · 2025Review
- HIV-1 infection facilitates Alzheimer's disease pathology in humanized APP knock-in immunodeficient mice.NeuroImmune pharmacology and therapeutics · 2025Article
- Multi-omic Characterization of HIV Effects at Single Cell Level across Human Brain Regions.bioRxiv : the preprint server for biology · 2025Article
- Single-cell analysis of CD14Frontiers in immunology · 2025Article
- In situ analysis of neuronal injury and neuroinflammation during HIV-1 infection.Retrovirology · 2024Article
- Impaired extinction of cocaine seeking in HIV-infected mice is accompanied by peripheral and central immune dysregulation.Communications biology · 2024Article
- Accelerated Neuroimmune Dysfunction in Aged HIV-1-Infected Humanized Mice.Pharmaceuticals (Basel, Switzerland) · 2024Article
- HIV-1 infection of genetically engineered iPSC-derived central nervous system-engrafted microglia in a humanized mouse model.Journal of virology · 2023Article
- Genomic Exploration of the Brain in People Infected with HIV-Recent Progress and the Road Ahead.Current HIV/AIDS reports · 2023Review
- Impaired extinction of cocaine seeking in HIV-infected mice is accompanied by peripheral and central immune dysregulation.Research square · 2023Article
- Humanized Mice for Studies of HIV-1 Persistence and Elimination.Pathogens (Basel, Switzerland) · 2023Review
- A Review of the Development of Multitarget Molecules against HIV-TB Coinfection Pathogens.Molecules (Basel, Switzerland) · 2023Review
- Animal models for studies of HIV-1 brain reservoirs.Journal of leukocyte biology · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 2 institutions in 1 country.
Funding
Abstract
The HIV-1 often evades a robust antiretroviral-mediated immune response, leading to persistent infection within anatomically privileged sites including the CNS. Continuous low-level infection occurs in the presence of effective antiretroviral therapy (ART) in CD4+ T cells and mononuclear phagocytes (MP; monocytes, macrophages, microglia, and dendritic cells). Within the CNS, productive viral infection is found exclusively in microglia and meningeal, perivascular, and choroidal macrophages. MPs serve as the principal viral CNS reservoir. Animal models have been developed to recapitulate natural human HIV-1 infection. These include nonhuman primates, humanized mice, EcoHIV, and transgenic rodent models. These models have been used to study disease pathobiology, antiretroviral and immune modulatory agents, viral reservoirs, and eradication strategies. However, each of these models are limited to specific component(s) of human disease. Indeed, HIV-1 species specificity must drive therapeutic and cure studies. These have been studied in several model systems reflective of latent infections, specifically in MP (myeloid, monocyte, macrophages, microglia, and histiocyte cell) populations. Therefore, additional small animal models that allow productive viral replication to enable viral carriage into the brain and the virus-susceptible MPs are needed. To this end, this review serves to outline animal models currently available to study myeloid brain reservoirs and highlight areas that are lacking and require future research to more effectively study disease-specific events that could be useful for viral eradication studies both in and outside the CNS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.